This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Funding For AIDS Drugs Not Included In Senate Spending Bill

WILL FORCE STATES TO DISENROLL CURRENT ADAP CLIENTS

WASHINGTON, March 19, 2013 /PRNewswire-USNewswire/ -- In an unprecedented action by the federal government, the spending bill about to be passed by the United States Senate does not include funding needed to continue lifesaving medications to nearly 8,000 low-income people with HIV.  As part of the bill that will fund the federal government through the end of September, both the House of Representatives and the Senate have failed to continue $35 million for the AIDS Drug Assistance Program (ADAP). The spending bill also failed to continue $10 million for clinical medical care provided through Part C of the Ryan White Program.

(Logo: http://photos.prnewswire.com/prnh/20110412/DC82138LOGO)

"While we have faced severe waiting lists for people wanting to take medications in the past," said Carl Schmid, Deputy Executive Director of The AIDS Institute, "failure to provide funding for existing patients is a dangerous unprecedented action by the U.S government."  Once a patient begins antiretroviral treatment, the drugs must be taken every day without interruption or the person can quickly become ill. Resistance to medications can occur, even with a single missed dose, leading to serious health complications and higher health costs.   

President Obama increased funding for ADAP on World AIDS Day, 2011 in response to the growing wait lists and at the urging of several Members of Congress.  Earlier House and Senate versions of the FY13 spending bills continued this money, and even included significant increases to address the eight percent growth in clients ADAP experienced last year. 

Senate Appropriations Subcommittee Chairman Tom Harkin attempted to address the ADAP funding cut with an amendment that would have resolved this issue, among other things.  Unfortunately, it failed on a party-line vote on the Senate floor. Without the $35 million continuation  in ADAP funding, states such as Alabama, Florida, Georgia, Illinois, Nebraska, Tennessee and several others will likely stop providing medications to many ADAP clients.

"We hope that before the bill is finalized and sent to the President, Congress will see fit to find a way to continue this funding to avoid any interruptions in lifesaving care and treatment  With sequestration and discussion of further budget cuts, continuation of this funding is an absolute necessity," concluded Schmid.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs